N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
University of California, San Francisco
University of California, San Francisco
Dana-Farber Cancer Institute
Medical University of South Carolina
University of Utah
Washington University School of Medicine
Washington University School of Medicine
Northwestern University
Washington University School of Medicine
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Case Comprehensive Cancer Center
Washington University School of Medicine
University of Arkansas